» Articles » PMID: 1649297

Selective Blockage of Delta Opioid Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice

Overview
Specialty Pharmacology
Date 1991 Jul 1
PMID 1649297
Citations 155
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, we demonstrated that delta opioid binding sites are involved in the development of morphine tolerance and dependence. In our present work, we studied the effect of the potent and selective delta antagonist, naltrindole (NTI), and its nonequilibrium analog, naltrindole 5'-isothiocyanate (5'-NTII), on the development of morphine tolerance and dependence in mice. In the acute model, mice injected with 100 mg/kg of morphine sulfate s.c. displayed acute tolerance 4 hr later as evidenced by a greater than 3-fold increase of the ED50 of morphine sulfate when compared to that of control mice. The acute tolerance was accompanied by the development of acute physical dependence as seen by the dramatic decrease in the amount of naloxone required to precipitate withdrawal jumping. Likewise, in the chronic model s.c. implantation of morphine pellets (75 mg free base) for 3 days produced tolerance and physical dependence. The ED50 of morphine sulfate in this case was increased by about 19-fold and the amount of naloxone needed to precipitate withdrawal jumping was 40 times lower than that required for acutely dependent mice. The development of acute tolerance and dependence was suppressed markedly in mice pretreated with NTI before induction of tolerance and dependence with 100 mg/kg of morphine sulfate. Multiple administration of either NTI or 5'-NTII before and during implantation with morphine base pellets also inhibited substantially the development of morphine tolerance and dependence.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits.

Davis M Drugs. 2025; 85(2):215-230.

PMID: 39873915 DOI: 10.1007/s40265-024-02128-y.


Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice.

Mueller L, Wexler R, Lovejoy D, Stein R, Slee A Psychopharmacology (Berl). 2024; 241(8):1565-1575.

PMID: 38630316 PMC: 11269454. DOI: 10.1007/s00213-024-06582-0.


Peptide-derived ligands for the discovery of safer opioid analgesics.

Eliasof A, Liu-Chen L, Li Y Drug Discov Today. 2024; 29(5):103950.

PMID: 38514040 PMC: 11127667. DOI: 10.1016/j.drudis.2024.103950.


Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.

Li Y, Eans S, Ganno-Sherwood M, Eliasof A, Houghten R, McLaughlin J Molecules. 2023; 28(22).

PMID: 38005269 PMC: 10674865. DOI: 10.3390/molecules28227548.


Tryptophan Substitution in CJ-15,208 ([Phe-D-Pro-Phe-Trp]) Introduces δ-Opioid Receptor Antagonism, Preventing Antinociceptive Tolerance and Stress-Induced Reinstatement of Extinguished Cocaine-Conditioned Place Preference.

Scherrer K, Eans S, Medina J, Senadheera S, Khaliq T, Murray T Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765026 PMC: 10535824. DOI: 10.3390/ph16091218.